Roche said Wednesday that an experimental cancer immunotherapy directed against a target called TIGIT failed to slow the progression of a less common but aggressive type of lung cancer.
Anyone 50 years and older could soon be eligible for a second booster dose of the Moderna or Pfizer-BioNtech COVID-19 vaccine. The FDA is expected to authorize the additional booster shots without holding a meeting of its independent vaccine advisors.